Castle Biosciences
CSTL
180 hedge funds and large institutions have $516M invested in Castle Biosciences in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 77 increasing their positions, 54 reducing their positions, and 44 closing their positions.
79% more call options, than puts
Call options by funds: $200K | Put options by funds: $112K
43% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.89% less ownership
Funds ownership: 94.63% → 90.74% (-3.9%)
9% less funds holding
Funds holding: 197 → 180 (-17)
27% less capital invested
Capital invested by funds: $706M → $516M (-$190M)
34% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$14.8M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$13.8M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$12.1M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$9.04M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$18.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.3M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$11M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.7M |
CSTL Hedge Fund Activity: Q1 2025 in Review
180 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2025, worth a combined $516M — down 27% from $706M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of CSTL and 29 opened new positions — a net loss of 15 holders — while 54 trimmed existing stakes and 77 added.
The largest buyer was Schroder Investment Management Group, opening a new position worth an estimated $14.8M. The largest seller was Wasatch Advisors, cutting an estimated $19.7M.
- 180 institutional investors held Castle Biosciences (CSTL) as of Q1 2025, down from 197 in Q4 2024.
- Funds reported $516M of Castle Biosciences stock for Q1 2025, down 27% quarter-over-quarter.
- 29 funds opened new Castle Biosciences positions in Q1 2025 and 44 closed out, a net change of -15 holders.
- The largest Castle Biosciences buyer in Q1 2025 was Schroder Investment Management Group, an estimated $14.8M added.
- The largest Castle Biosciences seller in Q1 2025 was Wasatch Advisors, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2025.